DK1691827T3 - Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock - Google Patents

Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock

Info

Publication number
DK1691827T3
DK1691827T3 DK05752350T DK05752350T DK1691827T3 DK 1691827 T3 DK1691827 T3 DK 1691827T3 DK 05752350 T DK05752350 T DK 05752350T DK 05752350 T DK05752350 T DK 05752350T DK 1691827 T3 DK1691827 T3 DK 1691827T3
Authority
DK
Denmark
Prior art keywords
sub
moiety
chain
peptide
beta
Prior art date
Application number
DK05752350T
Other languages
Danish (da)
English (en)
Inventor
Peter Petzelbauer
Kai Zacharowski
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0108704A external-priority patent/AT414097B/de
Priority claimed from AT0004005A external-priority patent/AT501263B1/de
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Application granted granted Critical
Publication of DK1691827T3 publication Critical patent/DK1691827T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05752350T 2004-06-25 2005-06-24 Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock DK1691827T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0108704A AT414097B (de) 2004-06-25 2004-06-25 Pharmazeutische zubereitung zur behandlung von schock
AT0004005A AT501263B1 (de) 2005-01-13 2005-01-13 Pharmazeutische zubereitung zur behandlung von schock
PCT/AT2005/000228 WO2006000007A1 (de) 2004-06-25 2005-06-24 Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock

Publications (1)

Publication Number Publication Date
DK1691827T3 true DK1691827T3 (da) 2009-12-14

Family

ID=35058593

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05752350T DK1691827T3 (da) 2004-06-25 2005-06-24 Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock

Country Status (20)

Country Link
US (1) US20080249006A1 (pt)
EP (1) EP1691827B1 (pt)
JP (1) JP2008503503A (pt)
AT (1) ATE439856T1 (pt)
AU (1) AU2005256121B2 (pt)
BR (1) BRPI0506148A (pt)
CA (1) CA2544676A1 (pt)
CY (1) CY1109631T1 (pt)
DE (1) DE502005007926D1 (pt)
DK (1) DK1691827T3 (pt)
EA (1) EA008799B1 (pt)
ES (1) ES2331958T3 (pt)
HK (1) HK1093308A1 (pt)
HR (1) HRP20090618T1 (pt)
IL (1) IL173969A (pt)
NZ (1) NZ545634A (pt)
PL (1) PL1691827T3 (pt)
PT (1) PT1691827E (pt)
SI (1) SI1691827T1 (pt)
WO (1) WO2006000007A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502987A1 (de) * 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
DE602007002553D1 (de) 2006-02-23 2009-11-05 Fibrex Medical Res & Dev Gmbh Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
ES2371038T3 (es) * 2006-02-23 2011-12-26 Fibrex Medical Research & Development Gmbh Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.
JP2010540892A (ja) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US7884074B2 (en) 2008-05-15 2011-02-08 Ikaria Development Subsidiary Two, LLC Compounds and methods for prevention and/or treatment of inflammation using the same
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
SK7062003A3 (en) * 2000-12-12 2003-11-04 Fibrex Medical Res & Dev Gmbh Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
ATE345788T1 (de) * 2001-03-06 2006-12-15 Dorian Bevec Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ES2371038T3 (es) * 2006-02-23 2011-12-26 Fibrex Medical Research & Development Gmbh Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.

Also Published As

Publication number Publication date
BRPI0506148A (pt) 2006-10-24
US20080249006A1 (en) 2008-10-09
EA200600561A1 (ru) 2006-08-25
SI1691827T1 (sl) 2010-01-29
HRP20090618T1 (hr) 2010-01-31
PL1691827T3 (pl) 2010-01-29
NZ545634A (en) 2009-09-25
CY1109631T1 (el) 2014-08-13
PT1691827E (pt) 2009-11-23
DE502005007926D1 (de) 2009-10-01
ATE439856T1 (de) 2009-09-15
IL173969A (en) 2011-06-30
CA2544676A1 (en) 2006-01-05
AU2005256121B2 (en) 2011-03-03
WO2006000007A1 (de) 2006-01-05
HK1093308A1 (en) 2007-03-02
AU2005256121A8 (en) 2008-08-21
EP1691827B1 (de) 2009-08-19
JP2008503503A (ja) 2008-02-07
AU2005256121A1 (en) 2006-04-27
EA008799B1 (ru) 2007-08-31
EP1691827A1 (de) 2006-08-23
ES2331958T3 (es) 2010-01-21
IL173969A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
DK1691827T3 (da) Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
NO20063026L (no) Antistoffer
ATE446310T1 (de) An mhc-moleküle bindende tumor-assoziierte peptide
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK2044125T3 (da) Sammensætninger og fremgangsmåder til indgivelse af aktiverede anti-ras-antistoffer i celler
DE60034888D1 (de) N-substituierte l-aminosäuren enthaltende peptide, zur prävention der beta-strang assoziation
WO2005002500A3 (en) Inhibitors of coronavirus
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
UA91497C2 (ru) ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА
BR0313019A (pt) Compostos que se ligam a p-selectina
ATE485831T1 (de) Behandlung von neurodegeneration
ATE405827T1 (de) Screening-verfahren
HK1083850A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
WO2007020405A3 (en) Integrin i-domain binding peptides
Mastrangelo et al. C26 TREATMENT OF RESPIRATORY INFECTIONS: Identification Of Novel Peptide Inhibitors Of Rsv Replication Based On Human Nucleolin
NZ591989A (en) Prion-specific peptide reagents
SE0002364D0 (sv) Growth Factors